Asthma and breathing
Conditionally acceptable biologics: interleukin and TSLP inhibitors
Interleukin and TSLP inhibitors, biologic
Other names: dupilumab, Dupixent, mepolizumab, Nucala, benralizumab, Fasenra
Wait
2 weeks
ground trial when starting
Different waits apply in other cases.
FAA label
CONDITIONALLY ACCEPTABLE
The FAA lists dupilumab, mepolizumab, benralizumab, reslizumab, tezepelumab and related biologics as conditionally acceptable, depending on the underlying condition, with a two-week ground trial when starting and four hours of no-fly after each dose.
Track your medicationsCompare FAA documents: Conditionally acceptable biologics: interleukin and TSLP inhibitorsWhat each of the two FAA documents says, in plain wordsOpen
Wait
- 4 hours no-fly after each dose
- a forty-eight hour ground trial when changing from one biologic or biosimilar to another for the same indication
Changing from one biologic or biosimilar to another for the same indication requires a 48-hour ground trial.
The FAA's CACI – Asthma Worksheet says monoclonal antibodies are not acceptable for CACI; it does not name these medicines.
- 14 days after starting: ground observation
- 4 hours after each dose: no flying
Show the FAA's words: Conditionally acceptable biologics: interleukin and TSLP inhibitorsThe official FAA wording: three passages, each with its document and dateOpen
Initial observation: All require a 2-week no-fly/ground trial to verify no side effects.
CONDITIONALLY ACCEPTABLE BIOLOGIC MEDICATIONS Monotherapy — Dependent on underlying condition(s), see those pages.
Interleukin Inhibitors: benralizumab (Fasenra), brodalumam (Siliq), canakinumab (Ilaris), dupilumab (Dupixent), mepolizumab (Nucala), reslizumab (Cinqair), rilonacept (Arcalyst), 4 hours. TSLP (thymic stromal lymphopoietin) Inhibitor: tezepelumab (Tezspire), 4 hours
Changing from one biologic/biosimilar to another for the same indication requires a forty-eight (48) hour ground trial to mitigate any aeromedical risk.
Acceptable Medications
NOT acceptable for CACI:
Monoclonal antibodies